Multidrug-resistant tuberculosis

Vista senzilla d'ítem
dc.contributor.authorCaminero, José A .
dc.contributor.authorGarcía-Basteiro, Alberto L.
dc.contributor.authorRendon, Adrian
dc.date.accessioned2019-09-23T13:57:24Z
dc.date.available2019-09-23T13:57:24Z
dc.date.issued2019-07-27
dc.date.updated2019-08-09T18:00:35Z
dc.description.abstractThe ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti-tuberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity.
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn0140-6736
dc.identifier.pmid23190229
dc.identifier.urihttps://hdl.handle.net/2445/140760
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1016/S0140-6736(19)30696-8
dc.relation.ispartofThe Lancet, 2019, vol. 394, num. 10195, p. 298
dc.relation.urihttp://dx.doi.org/10.1016/S0140-6736(19)30696-8
dc.rights(c) Elsevier, 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationTuberculosi
dc.subject.classificationResistència als medicaments
dc.subject.otherTuberculosis
dc.subject.otherDrug resistance
dc.titleMultidrug-resistant tuberculosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
CamineroJA_Lancet_2019_Correspondence.pdf
Mida:
66.23 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (ISGlobal)